Table 4– Associations between biomarkers and disease progression
VariableItemsDFPDHR (95% CI)p-value#Adjusted HR (95% CI)p-value
TP53 statusWild-type70 (49.3)59 (54.6)10.4510.64
Mutated72 (50.7)49 (45.4)0.86 (0.59–1.27)0.91 (0.62–1.40)
Type0 – others124 (88.6)84 (80.8)10.1910.14
1 – all G>T16 (11.4)20 (19.2)1.4 (0.9–2.3)1.46 (0.89–2.41)
KRAS statusWild-type118 (84.3)85 (78)10.2610.46
Mutated22 (15.7)24 (22)1.30 (0.82–2.06)1.19 (0.75–1.90)
KRAS/TP53 statusOtherwise138 (97.9)102 (93.6)10.0710.21
Both mutated3 (2.1)7 (6.4)2.08 (0.95–4.57)1.67 (0.74–3.77)
p53 haplotypeGNA-CDP33 (23.6)23 (21.1)1.07 (0.64–1.76)0.951.16 (0.69–1.96)0.93
GNA-CNP17 (12.1)15 (13.8)1.15 (0.63–2.07)1.52 (0.63–2.11)
Others65 (46.4)49 (45)1.15 (0.69–1.92)1.11 (0.66–1.89)
GNA-GNA25 (17.9)22 (20.2)11
EGFR status+Wild-type62 (87.3)51 (86.4)10.4810.68
Mutated9 (12.7)8 (13.6)1.31 (0.62–2.80)0.97 (0.67–1.38)
  • Data are presented as n (%), unless otherwise stated. DF: disease free; PD: progressive disease; HR: hazard ratio. #: Fine and Gray model with centre stratification; : Fine and Gray model with centre stratification adjusted on pT and pN; +: the group of cases analysed included 130 adenocarcinomas.